Maia Biotechnology (MAIA)Director bought ~$100K

~$100K

Approx. value · 82K sh @ $1.22

1.25M

Holds after · shares reported

Traded

Dec 22, 2025

Filed

Dec 23, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 19, 2022InsiderDirector purchased ~$10K of MAIA shares in the open market
2. Nov 21, 2025Insider · First buy since 2023CEO purchased ~$1.7K of MAIA shares in the open market
3. Nov 24, 2025Insider · 2 peopleInsiders: 2 purchases (~$20K)
4. Nov 25, 2025Insider · 3 peopleInsiders: 3 purchases (~$35K)
5. Nov 26, 2025Insider · 3 peopleInsiders: 3 purchases (~$60K)
6. Nov 28, 2025Insider · 2 peopleInsiders: 2 purchases (~$77K)
7. Dec 5, 2025Insider · 1 personInsiders: 3 purchases (~$16K)
8. Dec 16, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
9. Dec 22, 2025 · this disclosureInsider · 3 insiders in a week, 7th time since 2022Director purchased ~$100K of MAIA shares in the open market

What came next

1. Dec 22, 2025Insider · 2 peopleInsiders: 2 purchases (~$120K)
2. Mar 2, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
3. Mar 27, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 27, 2026, the Board of Directors of MAIA Biotechnology, Inc. (the “Company”) approved one-time bonus payments of $312,610 to Vlad Vitoc, the Company’s Chief Executive Officer and $50,000 to Jeffrey Himmelreich, the Company’s Head of Finance, in consideration for their efforts in connection with the Company’s recent capital raise.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Maia Biotechnology

For Maia Biotechnology, OQRO holds 7 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MAIA page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Maia Biotechnology

• SEC Form 4Sep 15, 2026
• SEC Form 4Sep 14, 2026
• SEC Form 4Sep 2, 2026
• SEC Form 4Sep 2, 2026
• SEC Form 4Sep 2, 2026
• SEC Form 4Aug 26, 2026

Everything OQRO holds on this company is on its MAIA page.